Amarin announces upcoming presentations at ESC Congress 2025

Amarin (AMRN) Corporation announced upcoming presentations at the European Society of Cardiology, ESC, Congress 2025, August 29th-September 1st, in Madrid, Spain, where new data will further illuminate the multifaceted cardioprotective effects of icosapent ethyl, IPE. Data to be featured at ESC 2025 will provide deeper insight into the potential role of IPE in reducing cardiovascular risk through multiple mechanisms, including effects on inflammation, lipoprotein oxidation, CV risk associated with CV-kidney-metabolic, CKM, syndrome, and risk and duration of hospitalizations. Highlights include new analyses from the REDUCE-IT trial evaluating the clinical benefit of IPE, alongside mechanistic studies investigating the impact of eicosapentaenoic acid, EPA, on inflammasome activation, lipoprotein oxidation, and pro-inflammatory protein expression in endothelial cells under conditions of oxidative stress.